Skylar Jeremias

September 23, 2021

Misconceptions about the safety and necessity of vaccines were cited as the main reasons for lower-than-recommended vaccination rates among patients with multiple sclerosis (MS), according to new research.

September 21, 2021

Polymerase chain reaction–based comprehensive genomic profiling testing provided useful information for more than 94% of samples, including 81% of samples that normally would not have been tested, suggesting that more patients may benefit from CGP testing than anticipated.

September 20, 2021

Byooviz becomes the first FDA-approved ophthalmology biosimilar and the first FDA-approved biosimilar referencing Lucentis (ranibizumab), according to a statement from developers Samsung Bioepis and Biogen.

September 18, 2021

Investigators confirmed prognostic biomarkers for premenopausal patients with hormone receptor–positive (HR+) and human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer, which could potentially be used to inform treatment decisions.

September 16, 2021

Non-white patients with multiple sclerosis (MS), particularly African American and Hispanic American patients, were found to experience a higher level of overall disability and more severe symptoms, highlighting current disparities in this disease.

September 15, 2021

A literature review detailed the multitude of ways that liquid biopsy can be used to aid the treatment of patients with cancer, including aiding in screening, recurrence surveillance, genomic profiling, and therapeutic decision-making.

September 15, 2021

Samsung Bioepis found during a 5-year follow-up study that Ontruzant, the company’s trastuzumab biosimilar, had comparable cardiac safety and long-term efficacy with the reference product Herceptin.

September 11, 2021

Investigators identified 5 mutated genes that could serve as biomarkers for disease prognosis and clinical outcomes associated with pancreatic ductal adenocarcinoma, a common cancer with a high mortality rate and poor prognosis.

September 10, 2021

Bio-Thera Solutions and Sandoz have partnered for to allow for the commercialization of BAT1706, a bevacizumab biosimilar referencing Avastin, for the treatment of several forms of cancer.

September 08, 2021

In a survey, researchers indicated that the COVID-19 pandemic has placed extra barriers, including a lack of accessibility to patients and competing responsibilities, that have resulted in halts or delays to research on multiple sclerosis (MS) rehabilitation and quality of life.